Business Context and Reporting Period
This Form 6-K filing by Bionomics Limited (not Neuphoria Therapeutics Inc.) covers the period ended March 31, 2022. The report, dated April 29, 2022, serves to furnish the Company's Appendix 4C Quarterly Cashflow Report released to the Australian Securities Exchange (ASX) to U.S. investors.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document acts as a cover sheet referencing an attached exhibit (Exhibit 99.1) containing the detailed quarterly cashflow report, but the numerical data from that exhibit is not included in the provided text.
Material Changes
The filing text does not provide information regarding material changes versus the prior comparable period. Specific financial comparisons are contained within the referenced Exhibit 99.1, which is not detailed in this summary text.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, guidance, outlook, risks, contingencies, or unusual items. The document strictly confirms the submission of the quarterly cashflow report required by Australian regulations.
Investor Verification Checklist
- Verify the correct registrant name is Bionomics Limited, not Neuphoria Therapeutics Inc.
- Locate and review Exhibit 99.1 (Appendix 4C) to obtain actual cashflow figures for the period ended March 31, 2022.
- Confirm the filing date of April 29, 2022, aligns with the Company's ASX reporting schedule.